While current brain-computer interfaces (BCIs) are for medical patients, the timeline for healthy individuals to augment their brains is rapidly approaching. A child who is five years old today might see the first healthy human augmentations before they graduate high school, signaling a near-term, transformative shift for society.

The success of GLP-1s like Ozempic, which address weight loss, addiction, and metabolic fitness, has made the public more receptive to longevity drugs. People now better understand how a single drug targeting a core mechanism (like metabolic health) can have widespread, seemingly magical downstream benefits.

Like AI before ChatGPT, longevity operates largely outside public consciousness. It needs a single, undeniable breakthrough—a widely available drug that effectively extends healthspan—to capture the public's imagination and trigger a massive shift in political and social attention.

The distinction between "diseases of late life" and aging itself is artificial. Conditions like Alzheimer's or most cancers are simply aspects of aging that have been given disease-like names. This unifies them as targets for a single, comprehensive anti-aging medical intervention.

Rather than confronting uncomfortable terms like "human enhancement," society adopts radical new technologies like vaccines or smartphones and simply redefines them as normal. People vote with their wallets for useful products long before they win an ethical debate, making the debate itself moot.

While the wealthy can access expensive protocols involving diagnostics and lifestyle optimization, these offer only marginal benefits. True, effective longevity will not come from this but from validated, mass-produced biotech drugs that target the core mechanisms of aging.

George Church predicts that reversing aging via somatic gene therapy will be the first truly mainstream genetic enhancement. Since aging will affect 90% of the population, therapies that restore youthful function in the elderly will have a massive impact and widespread adoption, becoming the "GLP-1 moment" for gene editing.

Anti-aging treatments will pay for themselves by eliminating the enormous medical costs of late-life health problems. This creates a powerful economic imperative for governments to ensure universal access, countering the common fear that such therapies will only be available to the wealthy.

While foundational, lifestyle improvements have a ceiling. The next major breakthroughs in extending health and lifespan, achieving "longevity escape velocity," will be delivered by advanced biotech like cellular reprogramming, not by the mass adoption of perfect diet, sleep, and exercise habits.